S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

Cancer Genetics Stock Price, News & Analysis (NASDAQ:CGIX)

$0.18
0.00 (0.00%)
(As of 12/5/2023 ET)
Today's Range
$0.18
$0.19
50-Day Range
$0.15
$4.61
52-Week Range
$2.11
$17.50
Volume
28,510 shs
Average Volume
2.44 million shs
Market Capitalization
$725,087.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CGIX stock logo

About Cancer Genetics Stock (NASDAQ:CGIX)

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

CGIX Stock Price History

CGIX Stock News Headlines

Cancer Genetics (NASDAQ:CGIX) Now Covered by StockNews.com
See More Headlines
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CGIX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.33 million

Miscellaneous

Free Float
N/A
Market Cap
$725,087.50
Optionable
Not Optionable
Beta
2.72
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Andrew D. C. LaFrence
    President, Chief Executive & Financial Officer














CGIX Stock Analysis - Frequently Asked Questions

How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.1570 on January 1st, 2023. Since then, CGIX stock has increased by 13.1% and is now trading at $0.1775.
View the best growth stocks for 2023 here
.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?
How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CGIX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -